Efficacy and Tolerability of Entacapone as Adjunctive Therapy to Levodopa in Patients with Parkinson’s Disease and End-of-Dose Deterioration in Daily Medical Practice: An Open, Multicenter Study

Publisher： Karger

E-ISSN： 1421-9913|45|2|111-118

ISSN： 0014-3022

Source： European Neurology, Vol.45, Iss.2, 2001-02, pp. : 111-118

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of End-of-Dose Wearing-Off in Parkinson’s Disease: Stalevo® (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess®/Comtan® (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI Treatment

By  

European Neurology, Vol. 53, Iss. 4, 2005-07 ,pp. : 197-202

Karger

Access to resources Recommend Favorite

Is There a Difference between Levodopa/ Dopa-Decarboxylase Inhibitor and Entacapone and Levodopa/Dopa-Decarboxylase Inhibitor Dose Fractionation Strategies in Parkinson’s Disease Patients Experiencing Symptom Re-Emergence due to Wearing-Off?

By  

European Neurology, Vol. 61, Iss. 2, 2008-11 ,pp. : 69-75

Karger

Access to resources Recommend Favorite

Switch-Over from Tolcapone to Entacapone in Severe Parkinson’s Disease Patients

By  

European Neurology, Vol. 46, Iss. 1, 2001-07 ,pp. : 11-16

Karger

Access to resources Recommend Favorite

Safety and Tolerability of Pardoprunox, a New Partial Dopamine Agonist, in a Randomized, Controlled Study of Patients with Advanced Parkinson’s Disease

By  

European Neurology, Vol. 62, Iss. 1, 2009-04 ,pp. : 40-48

Karger

Access to resources Recommend Favorite

Cognitive Deterioration Rates in Patients with Parkinson’s Disease from Northeastern China

By  

Dementia and Geriatric Cognitive Disorders, Vol. 30, Iss. 1, 2010-08 ,pp. : 64-70

Karger

Access to resources Recommend Favorite